Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Moleculin Biotech, Inc. Director's Dealing 2022

Mar 3, 2022

34881_dirs_2022-03-02_78937c83-961e-4eb0-9c33-a01771ccc37e.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Moleculin Biotech, Inc. (MBRX)
CIK: 0001659617
Period of Report: 2022-03-01

Reporting Person: Yan Joy (Director)